Crescendo to attend upcoming investor conferences

Cambridge, UK, 16 December 2021 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be attending the following events. They look forward to meeting investors to discuss the Company's business strategy, technology, discovery platform and development programmes.

- **Kempen Life Sciences Virtual Crossover Conference, 6 January 2022**
- **40th Annual J.P. Morgan Healthcare Conference, 10-13 January 2022**
- **H.C. Wainwright BIOCONNECT Virtual Conference, 10-13 January 2022**
  Presentation at 7:00 am EST, 12:00 pm GMT, 10 January 2022

If you would like to meet the team at or around these events, please contact the Company via email at investors@crescendobiologics.com.

Please refer to the conference websites for further information and any updated schedules.

-Ends-

For more information, please contact:

Crescendo Biologics

Michael Booth, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Katie Duffell,
Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V_H domain building blocks

(Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda; a clinical development partnership for CB213 (a PD-1xLAG-3 multi-specific Humabody®) with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody®), which has recently successfully completed a Phase 1 clinical trial.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com and follow @HUMABODY.